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at a rate of approximately 1% per year. Therefore, the purpose of the
current studywas to describe the prevalence of MHDS, in particular de-
ﬁciencies of somatotropic, thyroid, adrenal, and gonadal axes in patients
with HFpEF compared with HFrEF.
Thirty-six male consecutive subjects with HFpEF were enrolled in
our tertiary referral center, and compared with 36 age-matched pa-
tients with HFrEF enrolled in the T.O.S.CA. Registry [4]. Particular careHeart failure
Hormonal deﬁciencies
CatabolicThe heart failure (HF) epidemic, its ominous prognosis (worse than
that of many cancers), and the huge direct and indirect costs for health
systems worldwide prompt the quest for novel pathophysiological
mechanisms and innovative therapeutic strategies. In this regard,
emerging evidence support the concept that multiple hormone deﬁ-
ciencies (MHD), particularly those affecting the anabolic drive, impact
on HF progression [1,2]. However, whereas consistent data coming
from several independent groups have documented the reduced activi-
ty of most anabolic axes in HF with reduced ejection fraction (HFrEF)
[1–3], to date no study has addressed the presence and prevalence of
the MHD Syndrome (MHDS) in HF with preserved ejection fraction
(HFpEF). This information appears relevant considering that HFpEF cur-
rently accounts for N50% of all heart failure patients and its prevalenceal Medical Sciences, Via Sergio
i).relative to heart failure with reduced ejection fraction (HFrEF) is rising
was given to select patients with comparable NYHA class. The diagnos-
tic criteria for HFrEF and HFpEF were those published by the recent
guidelines [5], and in addition, patients were aged N18 years, on stable
medications for at least three months including ß-blocker. Patients un-
dergoing an active hormone treatment, with known advanced kidney
disease (eGRF b30ml/min) or liver cirrhosis were excluded. All patients
included in the study underwent evaluation of blood chemistry and cir-
culating levels of total testosterone, dehydroepiandrosterone sulfate
(DHEA-S), thyroid hormones, insulin-like growth factor-1 (IGF-1).
Moreover, all patients performed a pituitary stimulatory test with GH
releasing hormone plus arginine, EKG and a complete doppler echocar-
diographic study. Left Ventricular (LV) volumes and LV ejection fraction
(LVEF) were calculated as previously described (Aplio XG imaging
system, Toshiba, Japan) [6]. Peak oxygen consumption (peak VO2) and
ventilatory efﬁciency (VE/VCO2 slope) were measured during a
bicycle cardiopulmonary exercise test (CPET) with a ramp protocol of
10 W/min continued until limiting symptoms [2]. Informed consent
was obtained from each patient. This study protocol was reviewed
and approved by the local Ethics Committee (rif. 151/16). All blood sam-
ples were collected by venipuncture in fasting patients, total testoster-
one was measured by the DPC Coat-A-Count RIA kit; DHEA-S was
measured by a solid-phase, competitive chemiluminescent enzyme im-
munoassay, while IGF-1 by a radioimmuno assay using a monoclonal
Table 1
Clinical parameters, blood chemistry, hormonal evaluations, echocardiographic and CPET
measures in HFpEF vs. HFrEF.
HFpEF
(n = 36)
HFrEF
(n = 36) p
Anthropometric
Age (mean) 66 ± 14 66 ± 9 ns
BMI (kg/m2) 29 ± 4 30 ± 5 ns
LVEF (%) 56 ± 2 30 ± 7 b0.01
Coronary artery disease (%) 30 56 b0.05
Hypertension (%) 80 45 b0.05
Diabetes (%) 51 43 ns
Atrial ﬁbrillation (%) 58 33 b0.05
NYHA (I/II/III) 8/22/6 2/28/6 ns
Echocardiographic and CPET ﬁndings
LVMi (g/m2) 120 ± 27 146 ± 37 0.02
RWT 0.31 ± 0.05 0.28 ± 0.05 ns
LVEDd (mm) 59 ± 6 66 ± 9 0.05
e/a 1.01 ± 0.5 1.05 ± 0.5 ns
e/e’ 11 ± 4 15 ± 7 0.05
Peak VO2 (mL/kg/min) 18 ± 4 18 ± 3 ns
VO2 AT (mL/kg/min) 13 ± 2.5 11.6 ± 4 ns
VE/VCO2 slope 27 ± 7 28 ± 6 ns
Watt max (W) 88 ± 20 86 ± 30 ns
Hormonal data
IGF-1 (ng/mL) 139 ± 44 101 ± 37 b0.01
Deﬁcit IGF-1 (%) 8 15 ns
GH deﬁciency (%) 19 44 b0.05
Total Testosterone (ng/mL) 520 ± 143 382 ± 211 ns
Testosterone deﬁcit (%) 14 38 b0.05
DHEA-S (ug/dL) 98 ± 86 78 ± 74 ns
Low DHEA-S (%) 41 45 ns
TSH (μU/mL) 2.1 ± 1.9 1.83 ± 1.7 ns
FT3 (pg/mL) 3.2 ± 1.4 2.71 ± 0.61 ns
FT4 (ng/mL) 1.3 ± 0.4 1.37 ± 0.2 ns
Low T3 (%) 6 4 ns
HFpEF: heart failure with preserved ejection fraction; HFrEF: heart failure with reduced
ejection fraction; LVEF: left ventricle ejection fraction; BMI: bodymass index; IGF-1: Insu-
lin-like Growth Factor-1; NYHA: New York Heart Association; LVMi: Left Ventricle Mass
indexed; RWT: relative wall thickness; LVEDd: left ventricle end-diastolic diameter; e/a;
e/e’; VO2: Oxygen uptake; AT: anaerobic threshold; VE: ventilation per minute; VCO2:
carbon dioxide production.
Continuous variables were expressed as mean ± SD.
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expressed as mean ± SD. Categorical variables were expressed as per-
centage. Differences between subgroups were evaluated by a
Student's t-test for unpaired data. Signiﬁcance was set at 5%. Statistical
analysis was performed using the SPSS 16.0 package (SPSS Inc., Chicago,
IL). Rates and proportions were compared between groups of interest
using the chi-square test. Biochemical hormone deﬁciencies (HD)0 deficit
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Fig. 1. Prevalence of hormone deﬁwere deﬁned as previously reported [2]: DHEA-S and IGF-1 below the
10th percentile of our sex and age-matched control population; serum
total testosterone levels below 300 ng/dL and free triiodotironine levels
(T3) below 2.0 pg/mL (in the presence of normal TSH levels), according
to the reference limit of our laboratory and congruent with current
guidelines. GH deﬁciency was diagnosed according to the Guidelines
of the Italian National Health Care System (nota 39), using a Growth
Hormone Releasing Hormone (GHRH) + Arginine test and BMI-
adjusted cut-offs (peak GH below 9 μg/L for patients ≤30 kg/m2 BMI
and 4.1 μg/L for patients with BMI N 30 kg/m2).
Clinical parameters, blood chemistry, hormonal evaluations, echo-
cardiographic and CPET measures in the two groups of HF patients are
shown in Table 1. As expected, HFpEF patients showed a mean LVEF of
56 ± 2% while HFrEF patients had a mean LVEF of 30 ± 7% (p b 0.01).
Overall, patients with HFpEF displayed lower prevalence of coronary
artery disease, higher percentage of systemic hypertension, atrial ﬁbril-
lation and, with regard to therapy, decreased use of beta-blockers (72%
vs 92% in HFrEF, data not shown). Patients with HFpEF also displayed
MHDS as depicted in Fig. 1. However, the most striking difference be-
tween the two groups was that almost half of HFpEF patients (46%)
did not display any HD, compared with only 4% in HFrEF. Also testoster-
one deﬁciency was more common in HFrEF vs. HFpEF subjects
(p b 0.05). No differences were found with regard to low T3 syndrome
and DHEA-S deﬁciency. Speciﬁcally, both GH and testosterone deﬁcien-
cies were more common in HFrEF than in HFpEF (respectively 44% vs.
19% and 38% vs 14% of enrolled patients, p b 0.05). Average circulating
levels of IGF-1 and total testosterone were 18% and 27% lower in
HFrEF compared with HFpEF, respectively. Peak oxygen consumption
and other CPET parameters were similar in the two subgroups,
conﬁrming comparable degrees of HF. HFrEF patients showed a signiﬁ-
cantly higher value of LV mass index and LV end-diastolic diameter
(Table 1). Moreover, HFrEF patients displayed higher LV ﬁlling pres-
sures as suggested by e/e′ ratio compared to patients with HFpEF.
To the best of our knowledge, this is the ﬁrst study to document the
occurrence of anabolic deﬁciencies in HFpEF. Although lower than in
HFrEF, prevalence of HD in HFpEF was remarkable in our population
of mild-to-moderate CHF, considering that more than half of HFpEF
had at least 1 hormone deﬁciency. Of note, GH/IGF-1 and testosterone
were the most affected axes since DHEA-S and thyroid hormone values
were not signiﬁcantly different between the two groups. Although this
study was not speciﬁcally designed at identifying the mechanisms of
the observed differences in endocrine defects between the two study
populations, one hypothesis can be put forward. Recently, it has been
demonstrated that patientswithHFpEF andHFrEF express different bio-
markers, leading to speculation that different pathophysiological path-
ways are involved in the two clinical syndromes [7]. Speciﬁcally,0 deficit
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ciencies in HFpEF vs. HFrEF.
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indices of myocardial stress/injury, such as NT-proBNP and high sensi-
tivity troponin T (hsTnT). Biomarkers of inﬂammation,ﬁbrosis, and ane-
mia are more prominent in HFpEF [7]. This contrasting biomarker
proﬁle observed in HFrEF may in turn lead to greater inhibition of ana-
bolic hormone biosynthesis compared to HFpEF. It is also possible that
the slightly lower mortality rates observed in HFpEF may be accounted
for by the decreased impairment of the anabolic drive. Accordingly,
higher levels of anabolic drive in HFpEF vs. HFrEF may be considered a
further peculiarity supporting the emerging paradigm of a syndrome
different from HFrEF. Comorbidities appear to play a pivotal role in
HFpEF driving myocardial dysfunction and remodeling [9]. In several
preliminary trials, MHDS correction was successfully tested in HFrEF
and it would be of utmost interest to determine whether such a phar-
macological approachmay be beneﬁcial also in HFpEF. When designing
therapeutic strategies, anabolic deﬁciencies could represent additional
biomarkers to evaluate the various phenotypes of HF [10,11].
In conclusion, we provide new evidence for the presence of MHDS
in HFpEF, although the impairment of the anabolic drive is less pro-
nounced than in patients with HFrEF. Further studies are needed to con-
ﬁrm the presence of anabolic deﬁciency in larger population of HFpEF
and its prognostic implication.
Conﬂict of interest
None.
Funding
The study was partially supported by unrestricted grants from
Merck Serono.References
[1] E.A. Jankowska, B. Biel, J. Majda, et al., Anabolic deﬁciency inmenwith chronic heart
failure: prevalence and detrimental impact on survival, Circulation 114 (2006)
1829–1837.
[2] M. Arcopinto, A. Salzano, E. Bossone, et al., Multiple hormone deﬁciencies in chronic
heart failure, Int. J. Cardiol. 184 (2015) 421–423.
[3] M. Arcopinto, A. Salzano, J. Isgaard, et al., Hormone replacement therapy in heart
failure, Curr. Opin. Cardiol. 30 (2015) 277–284.
[4] E. Bossone, G. Limongelli, G. Malizia, et al., The T.O.S.CA. Project: research, education
and care, Monaldi Arch. Chest Dis. 76 (2011) 198–203.
[5] P. Ponikowski, A.A. Voors, S.D. Anker, et al., 2016 ESC guidelines for the diagnosis
and treatment of acute and chronic heart failure: the task force for the diagnosis
and treatment of acute and chronic heart failure of the European Society of Cardiol-
ogy (ESC) developed with the special contribution of the heart failure association
(HFA) of the ESC, Eur. Heart J. (2016).
[6] A. Cittadini, A. Berggren, S. Longobardi, et al., Supraphysiological doses of GH induce
rapid changes in cardiac morphology and function, J. Clin. Endocrinol. Metab. 87
(2002) 1654–1659.
[7] S. Sanders-vanWijk, V. van Empel, N. Davarzani, et al., Circulating biomarkers of dis-
tinct pathophysiological pathways in heart failure with preserved vs. reduced left
ventricular ejection fraction, Eur. J. Heart Fail. 17 (2015) 1006–1014.
[8] G. Rengo, A. Lymperopoulos, C. Zincarelli, et al., Blockade of beta-adrenoceptors re-
stores the GRK2-mediated adrenal alpha(2)-adrenoceptor-catecholamine produc-
tion axis in heart failure, Br. J. Pharmacol. 166 (2012) 2430–2440.
[9] F. Triposkiadis, G. Giamouzis, J. Parissis, et al., Reframing the association and signif-
icance of co-morbidities in heart failure, Eur. J. Heart Fail. 18 (2016) 744–758.
[10] A.S. Coats, L, The management of heart failure with preserved ejection fraction
(HFpEF), Int. Cardiovasc. Forum J. 1 (2014) 108–112.
[11] J. Sanderson, Comments on the management of heart failure with preserved ejec-
tion fraction, Int. Cardiovasc. Forum J. 1 (2014).
